Novartis | NOVN - Operating Expenses


Novartis reported $9.8B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alcon AG USD 2.41B 123M Dec/2025
Almirall EUR 517.4M 32K Dec/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Autolus Therapeutics Ltd USD 96.76M 3.94M Dec/2025
Bayer EUR 10.33B 126M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Fresenius EUR 5.25B 337M Dec/2025
Fresenius Medical Care EUR 4.41B 27.91M Dec/2025
Galapagos EUR 120.26M 7.43M Dec/2025
Genmab DKK 798M 235M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
GRIFOLS EUR 1.71B 193M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.78B 669M Dec/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Orion EUR 367.1M 64.9M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Philips EUR 4.38B 405M Dec/2025
Recordati EUR 384.01M 82.67M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
UCB EUR 2.96B 196M Dec/2025